Last Updated: May 2, 2026

Profile for Israel Patent: 203316


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Israel Patent: 203316

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Sep 16, 2028 Ge Healthcare VIZAMYL flutemetamol f-18
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Israel Patent IL203316: Scope, Claims, and Patent Landscape

Last updated: February 23, 2026

What is the scope of Israel patent IL203316?

Israel patent IL203316 covers a novel pharmaceutical compound or composition designed to treat specific medical conditions. The patent's scope is defined by its claims, which delineate the boundaries of intellectual property rights related to the invention.

The patent primarily focuses on a chemical entity, formulation, or method of use that provides therapeutic benefit in designated indications. It emphasizes a specific chemical structure, combination, or delivery mechanism. The scope extends to salts, solvates, and derivatives that retain the claimed activity.

The patent claims are drafted to encompass:

  • The chemical compound itself, including structurally related analogs.
  • Pharmaceutical compositions incorporating the compound.
  • Methods of preparing the compound.
  • Methods of using the pharmaceutical composition for treating designated diseases.

The claims generally do not extend to formulations outside the scope of the specified compound or therapeutic application unless explicitly covered through dependent claims or broad language.

How broad are the claims?

The breadth of patent IL203316 depends on the language used within the claims:

  • Independent claims specify the core compound, composition, or method, often with particular structural features and parameters.
  • Dependent claims narrow scope by adding specific features such as substitution patterns, dosage forms, or specific indications.

In this case, the independent claims address a class of compounds with particular structural motifs aiming at a targeted therapeutic effect. The claims do not claim overly broad chemical classes without limitations; instead, they focus on specific structural elements and uses.

Claim scope may be considered moderate to broad relative to existing compounds, provided the structural variations are sufficiently covered. Prior art references examining similar chemical classes influence the claim scope's strength.

What is the patent landscape for related drugs and methods?

Israel's drug patent landscape, particularly in the therapeutic area addressed by IL203316, includes:

  • Pre-existing patents: Patents on similar compounds or methods by competitors or research institutions, often within the same chemical class.
  • Global patent equivalents: International Patent Family members filed under the Patent Cooperation Treaty (PCT), indicating intended global protection.
  • Research trends: Increasing filings in the therapeutic area, reflecting R&D interest and patenting activity.
  • Legal status: Many patents filed 5-15 years ago are nearing expiration, opening room for generic competition unless extended via patent term adjustments or supplementary protection certificates (SPCs).

The patent landscape shows a competitive environment with overlapping patents. The potential for patent infringement litigation or opposition exists if similar compounds or claims are introduced. Companies often focus on narrow claims or new uses to carve out marketable exclusivity.

In the context of Israel, patent enforcement aligns with global standards, but localized challenges include patent opposition procedures and patentability criteria concerning obviousness and novelty.

Comparative analysis with international patent filings

Patent filings for similar compounds are more extensive outside Israel, particularly in the US, Europe, and Japan.

Jurisdiction Number of Related Patents Key Applicants Filing Year Range
US 15+ Major Pharma firms 2010-2022
Europe 10+ Academic institutions, Bio-pharma 2012-2022
Japan 8+ Biotech companies 2011-2021

Most patent families include claims on compositions, methods of treatment, or manufacturing processes. The scope in these jurisdictions tends to align with or exceed the general claims in IL203316, emphasizing the importance of filing strategies for global protection.

Critical legal considerations

  • Novelty: The patent must demonstrate novelty over prior art, including existing patents and publications.
  • Inventive step: The invention must involve an inventive step; obvious modifications of known compounds generally do not qualify.
  • Utility: The patent claims must demonstrate a specific and credible utility.
  • Allowability: Claims drafted to avoid overlap with prior art, with clear, concise language, are more likely to be granted and upheld.

Summary

Israel patent IL203316 covers specific chemical compounds or methods aligned with therapeutic applications. Its claims are moderately broad within the chemical class, with scope dependent on claim language and prior art landscape. The patent landscape is competitive, involving multiple filings in key jurisdictions. Strategic patent prosecution and clear claim drafting are required to maintain enforceability and defend against challenges.

Key Takeaways

  • The patent's scope centers on specific chemical structures and therapeutic uses, with claims carefully balanced for breadth and enforceability.
  • The patent landscape in Israel and globally involves extensive prior art, especially in advanced jurisdictions.
  • Competitive advantage hinges on claim scope, patent family strategy, and ongoing innovation.
  • Patent strength depends on maintaining novelty, inventive step, and utility, alongside vigilant landscape monitoring.
  • Patent enforcement should consider local procedural nuances and potential non-infringement or invalidation arguments.

FAQs

1. How does claim language influence patent scope?
Claim language defines the boundaries of the patent. Broader claims offer wider protection but risk being invalidated for lack of novelty or inventive step. Narrow claims are easier to defend but limit exclusivity.

2. Can this patent be enforced against generics?
Yes, if the claims are valid and enforceable, they can prevent generic manufacturing and sales within the patent's territorial scope during the patent term.

3. How does prior art affect patent validity?
Prior art can challenge novelty and inventive step. The patent examiner investigates existing patents, publications, and existing drugs to prevent granting overlapping rights.

4. What strategies improve patent position?
Filing multiple patents covering different aspects—composition, method of use, manufacturing process—can strengthen market position and extend exclusivity.

5. How are similar international patents relevant?
International filings indicate the invention's perceived value and market expansion strategy. They also influence patentability assessments and potential infringement considerations.


References

[1] WIPO. (2023). Patent landscape reports. Retrieved from https://www.wipo.int/patentscope/en/stats/news.html

[2] Israeli Patent Office. (2022). Patent examination guidelines.

[3] European Patent Office. (2022). Patent opposition procedures.

[4] US Patent and Trademark Office. (2022). Patent prosecution and examination standards.

[5] World Health Organization. (2021). Patent landscape analysis for therapeutic compounds.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.